TargetBeta
INSR
insulin receptor · also CD220 · CD molecules
8 programs in company-led studies act on INSR, from 5 companies: 1 in phase 3, 6 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (7 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| insulin degludecrule | Novo Nordisk | phase 4 | 1084 running | – | ChEMBL |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 1462 running | – | ChEMBL |
| insulin icodecrule | Novo Nordisk | phase 4 | 302 running | – | ChEMBL |
| Insulin Glarginerule | Sanofi | phase 4 | 1901 running | – | ChEMBL |
| Insulinrule | Pfizer | phase 4 | 501 running | – | ChEMBL |
| insulin glulisinerule | Sanofi | phase 4 | 430 running | – | ChEMBL |
| linsitinibrule | Astellas Pharma | phase 3 | 132 running | IGF1R | ChEMBL |
| LY3938577 | Eli Lilly | phase 2 | 31 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Diabetes Mellitus, Type 1, 7 programs
- Diabetes Mellitus, Type 2, 7 programs
- Diabetes Mellitus, 5 programs
- Adrenocortical Carcinoma, 1 program
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Diabetes, Gestational, 1 program
- Drug-Related Side Effects and Adverse Reactions, 1 program
- Glucose Intolerance, 1 program
- Graves Ophthalmopathy, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026LY3938577 · Eli Lilly · phase 2 · NCT07215312
- Dec 2026Insulin Aspart · Novo Nordisk · phase 4 · NCT05221359
- Jan 25, 2027insulin icodec · Novo Nordisk · phase 4 · NCT07076199
- Jun 30, 2028linsitinib · Astellas Pharma · phase 3 · NCT07753603
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.